LiteBC

Company Overview

Snapshot

Founded in November 2019 by Dr. Or Peleg and Barry (Boris) Loevsky, LiteBC operates with 11–50 employees. The company has secured funding across five rounds from three investors, with a notable grant received in August 2025 from the Israel Innovation Authority.

Business overview

LiteBC is developing a noninvasive blood count device designed for real-time, in-vivo monitoring of blood cells. Its core technology utilizes advanced imaging with multiple channels to overcome scattering, allowing users to place a handheld optical probe on a patient's lip for analysis. The device, currently in clinical trials, measures various blood parameters including white and red blood cells, differential counts, relative red blood cell volume, and hemoglobin. LiteBC aims to transform complete blood counts into a simple, accessible, and continuous measurement, serving the healthcare and life sciences sectors, particularly providers, within the digital health and medical technologies market.

Company Intelligence Q&A

What is LiteBC's primary product?

LiteBC's primary product is HemoScope, a noninvasive blood count device designed for real-time, in-vivo monitoring of blood cells.

When was LiteBC founded and by whom?

LiteBC was founded in November 2019 by Dr. Or Peleg and Barry (Boris) Loevsky.

Has LiteBC received any grants?

Yes, in August 2025, LiteBC secured a grant from the Israel Innovation Authority.

When did LiteBC last raise a funding round?

LiteBC raised a funding round in January 2025, with IN Venture participating as a lead investor.

Which investors have participated in LiteBC's funding rounds?

Entrée Capital has participated in multiple funding rounds for LiteBC, including a seed round in November 2023 and a pre-seed round in January 2020. IN Venture also led a funding round in January 2025.